How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Myotonic Dystrophy Therapeutics Market
- By Therapeutic Approach: Antisense Oligonucleotides (ASOs), Small Molecule Modulators, Gene Therapy, RNA Interference (RNAi), Protein Stabilizers
- By Targeted Symptoms: Muscle Weakness and Wasting, Cardiac Conduction Defects, Respiratory Complications, Cognitive Dysfunction, Endocrine Abnormalities
- By Delivery Method: Intravenous Injection, Intrathecal Injection, Oral Administration, Subcutaneous Injection
- By Stage of Development: Preclinical, Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, Approved Therapies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antisense Oligonucleotides (ASOs) leads By Therapeutic Approach at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Myotonic Dystrophy Therapeutics Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Approach 5
Targeted Symptoms 5
Delivery Method 4
Stage of Development 5
Companies profiled
Ionis Pharmaceuticals
Biogen
Fulcrum Therapeutics
Acceleron Pharma
Wave Life Sciences
Sarepta Therapeutics
PTC Therapeutics
Amicus Therapeutics
Dynacure
Avidity Biosciences
Roche
Novartis
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Ionis Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Biogen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Fulcrum Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Acceleron Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Wave Life Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sarepta Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →PTC Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Amicus Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Dynacure
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Avidity Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Roche
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Novartis
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sanofi
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Pfizer
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Bristol-Myers Squibb
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,817M by 2033 · 6.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antisense Oligonucleotides (ASOs)47.1
- Small Molecule Modulators11.5
- Gene Therapy9.0
- RNA Interference (RNAi)15.6
- Protein Stabilizers16.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$565.8M → $864.2M · 5.4%
Europe$394.3M → $726.0M · 7.9%
Asia Pacific$360.0M → $530.7M · 5.0%
Latin America$222.9M → $373.9M · 6.7%
Middle East and Africa$171.5M → $291.2M · 6.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.352026
6.372027
6.382028
6.402029
6.402030
6.422031
6.432032
6.442033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Ionis Pharmaceuticals19.6
- Biogen18.9
- Fulcrum Therapeutics7.6
- Acceleron Pharma8.6
- Wave Life Sciences9.3
- Sarepta Therapeutics8.1
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Approach23.6%
Targeted Symptoms33.3%
Delivery Method12.6%
Stage of Development30.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.0
- Europe26.1
- Asia Pacific19.0
- Latin America13.4
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals | 91 | 80 | 95 | 75 | 73 | 92 | 84 |
| Biogen | 73 | 68 | 87 | 76 | 87 | 90 | 80 |
| Fulcrum Therapeutics | 80 | 85 | 75 | 86 | 76 | 64 | 78 |
| Acceleron Pharma | 81 | 66 | 58 | 70 | 59 | 74 | 68 |
| Wave Life Sciences | 53 | 54 | 69 | 75 | 61 | 71 | 64 |
| Sarepta Therapeutics | 69 | 60 | 71 | 51 | 51 | 68 | 62 |
| PTC Therapeutics | 41 | 57 | 58 | 43 | 59 | 51 | 52 |
| Amicus Therapeutics | 38 | 39 | 55 | 41 | 51 | 52 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Ionis Pharmaceuticals
- Biogen
- Fulcrum Therapeutics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals | ✓ | ✓ | ✓ | ✓ | − | ◐ |
| Biogen | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Fulcrum Therapeutics | ✓ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Acceleron Pharma | ✓ | − | − | − | ◐ | ✓ |
| Wave Life Sciences | ◐ | − | ◐ | ✓ | − | ◐ |
| Sarepta Therapeutics | ✓ | ◐ | ◐ | ◐ | − | ✓ |
| PTC Therapeutics | − | ◐ | − | ◐ | − | ◐ |
| Amicus Therapeutics | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Ionis Pharmaceuticals84
2Biogen80
3Fulcrum Therapeutics78
4Acceleron Pharma68
5Wave Life Sciences64
6Sarepta Therapeutics62
7PTC Therapeutics52
8Amicus Therapeutics46
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Ionis PharmaceuticalsBiogenFulcrum Therapeutics
Challenger1
Strong scale, closing on the leaders.
Acceleron Pharma
Contender2
Focused players with pockets of strength.
Wave Life SciencesSarepta Therapeutics
Niche2
Specialists in a single segment or region.
PTC TherapeuticsAmicus Therapeutics
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Approach in North America, then scale across Myotonic Dystrophy Therapeutics Market — a $92M beachhead inside a $1.45B market.
Beachhead (SOM)$92Mobtainable near-term
Serviceable (SAM)$546Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Antisense Oligonucleotides (ASOs)
Best fit — highest urgency & budget in Therapeutic Approach.
Economic buyer79 fit
Small Molecule Modulators
Strong fit — clear ROI and a fast path to value.
End user68 fit
Gene Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Approach in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Targeted Symptoms & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Delivery Method
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve21%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Approach leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Myotonic Dystrophy Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified24%
Evaluation11%
Closed-won6%
$9.3KCAC
$37KLTV
4.0:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Myotonic Dystrophy Therapeutics Market is a durable-growth opportunity — $10.7B by 2033, compounding at 9.1%.
TAM · 2025$5.37Btoday
TAM · 2033$10.7Bforecast
CAGR9.1%2027–2033
Cumulative$70.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.7BTotal addressable market
SAM$4.12BServiceable available market
SOM$714MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.1% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Approach.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Approach moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.7BLarge & growingTAM by 2033 at 9.1% CAGR
$4.12BServiceable nowreachable with today’s model
$714MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.37BBear5.9% CAGR
$10.7BBase9.1% CAGR
$13.7BBull11.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Targeted Symptoms optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Myotonic Dystrophy Therapeutics Market — a $9.34B market by 2033. Plan: grow share from 7.8% to 13.4%.
Market size · 2033$9.34Btotal addressable
Market CAGR6.7%2027–2033
Target share13.4%from 7.8% today
Revenue ambition$1.25Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.8% | 13.4% | Behind |
| Revenue | $711M | $1.25B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 33.7% | 41.9% | On track |
| Customer retention | 91.0% | 95.5% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Approach
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Targeted Symptoms capability
A defensible second engine — invest in Targeted Symptoms to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Approach share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Targeted Symptoms
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $164M capacity & capability investment
- Greenlight bolt-on M&A in Targeted Symptoms
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Approach leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Myotonic Dystrophy Therapeutics Market conversation — a $1.21B market you can size, segment and defend in minutes.
Market size · 2033$1.21Btotal opportunity
Growth4.3%CAGR to 2033
Addressable buyers1,299+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Approach
Goal Grow share in Therapeutic Approach
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 2 mopayback period
$88K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Ionis PharmaceuticalsBiogenFulcrum TherapeuticsAcceleron PharmaWave Life SciencesSarepta TherapeuticsPTC TherapeuticsAmicus Therapeutics+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Myotonic Dystrophy Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Myotonic Dystrophy Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Myotonic Dystrophy Medication Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportMyopic Eye Drop Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportMyopia Suppression Glasses Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportMyopia Single Vision Lenses Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportMyopia Management System Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportMyopia Management Spectacles for Children Market
Market size, share, segmentation and regional forecast.
$934M market · 2025 base year
View reportMyopia Management Lens for Children Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportMyopia Management Lenses Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportMyopia Management Contact Lens for Children Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportMyopia Laser Therapy Instrument Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportMyopia Control Spectacle Lenses Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportMyopia Control Spectacle Lenses and Orthokeratology Lens Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.